KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung

Yokota,Keisuke; Sasaki,Hidefumi; Okuda,Katsuhiro; Shimizu,Shigeki; Shitara,Masayuki; Hikosaka,Yu; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/or.2012.1908

KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung

Authors:
- Keisuke Yokota
- Hidefumi Sasaki
- Katsuhiro Okuda
- Shigeki Shimizu
- Masayuki Shitara
- Yu Hikosaka
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan, Department of Pathology, National Hospital Organization Kinki-chuo chest Medical Center, Sakai, Osaka 591-8555, Japan
Published online on: July 13, 2012 https://doi.org/10.3892/or.2012.1908
Pages: 1187-1192

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recently, a novel fusion gene resulting from a linkage between the kinesin family member 5B gene (KIF5B; 10p11.22) and the rearranged during transfection gene (RET; 10q11.21) was identified in non-small cell lung cancer (NSCLC). However, the correlation between the KIF5B/RET fusion gene status and the clinicopathological features of surgically-treated lung cancer has not been well characterized. In this study, we have independently investigated the KIF5B/RET fusion gene status in 371 surgically-treated NSCLCs (270 were adenocarcinomas and 101 were squamous cell carcinomas), 60 breast cancers, 11 metastatic lung cancers from colon cancers and thyroid papillary adenocarcinoma cases at the Nagoya City University Hospital. The fusion gene status was analyzed by an RT-PCR-based assay and by using direct sequencing. We detected 3 of 270 cases of KIF5B/RET fusion genes in adenocarcinomas (1.1%) consisting of female and never smokers with mixed subtype adenocarcinomas. The fusion genes were detected exclusively with other mutations, such as EGFR, Kras, Braf, erbB2 mutations, and EML4/ALK fusion. KIF5B/RET fusion was not detected in the cases with squamous cell carcinoma or other types of cancers. From the 3 cases, 2 were KIF5B (exon 15); RET (exon 12) fusions with papillary dominant and 1 case was KIF5B (exon 22); RET (exon 12) fusion with solid dominant adenocarcinoma. The matched normal lung tissues did not display translocation. We reported KIF5B/RET fusion genes as a driver somatic mutation of lung adenocarcinomas. The cinicopathological backgrounds of the KIF5B/RET fusion-positive patients were similar with those of the EML4/ALK fusion-positive patients. The chimeric oncogene may be a promising molecular target for the personalized diagnosis and treatment of NSCLC.

View Figures

View References

1	Lee YJ, Kim JH, Kim SK, et al: Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer. 72:9–15. 2011. View Article : Google Scholar : PubMed/NCBI
2	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
3	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
4	Wong DW, Leung EL, So KK, et al: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from non smokers with wild-type EGFR and KRAS. Cancer. 115:1723–1733. 2009. View Article : Google Scholar : PubMed/NCBI
5	Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
6	Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ju YS, Lee WC, Shin JY, et al: Fusion of KIF5B and RET transforming gene in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 22:436–445. 2012. View Article : Google Scholar : PubMed/NCBI
8	Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 18:382–384. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kohno T, Ichikawa H, Totoki Y, et al: KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 18:375–377. 2012. View Article : Google Scholar : PubMed/NCBI
10	Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381. 2012. View Article : Google Scholar : PubMed/NCBI
11	Sasaki H, Endo H, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005. View Article : Google Scholar : PubMed/NCBI
12	Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
13	Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M and Fujii Y: Evaluation of Kras mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol. 6:15–20. 2011. View Article : Google Scholar : PubMed/NCBI
14	Sasaki H, Okuda K, Kawano O, et al: Nras and Kras mutation in Japanese lung cancer patients: genotyping analysis using LightCycler. Oncol Rep. 18:623–628. 2007.PubMed/NCBI
15	Sasaki H, Kawano O, Endo K, et al: Uncommon V599E Braf mutations in Japanese patients with lung cancer. J Surg Res. 133:203–206. 2006. View Article : Google Scholar : PubMed/NCBI
16	Grieco M, Santoro M, Berlingieri MT, et al: PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 60:557–563. 1990. View Article : Google Scholar : PubMed/NCBI
17	Alberti L, Carniti C, Miranda C, Roccato E and Pierotti MA: RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol. 195:168–186. 2003. View Article : Google Scholar : PubMed/NCBI
18	Zeng Q, Cheng Y, Zhu Q, et al: The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J Int Med Res. 36:656–664. 2008. View Article : Google Scholar : PubMed/NCBI
19	Dawson DM, Lawrence EG, MacLennan GT, et al: Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst. 90:519–523. 1998. View Article : Google Scholar : PubMed/NCBI
20	Ohshima Y, Yajima I, Takeda K, Kumasaka M, Matsumoto M and Kato M: c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines. PLoS One. 5:e102792010. View Article : Google Scholar : PubMed/NCBI
21	Tanizaki J, Okamoto I, Sakai K and Nakagawa K: Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer. 105:807–813. 2011. View Article : Google Scholar : PubMed/NCBI
22	Henderson YC, Ahn SH, Kang Y and Clayman GL: Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res. 14:4908–4914. 2008. View Article : Google Scholar : PubMed/NCBI
23	Carlomagno F, Anaganti S, Guida T, et al: BAY 43–9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 98:326–334. 2006.
24	Kim DW, Jo YS, Jung HS, et al: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 91:4070–4076. 2006. View Article : Google Scholar
25	Dawson S, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G and Rischin D: Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs. 19:547–552. 2008. View Article : Google Scholar : PubMed/NCBI
26	Takeuchi K, Choi YL, Togashi Y, et al: KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 15:3143–3149. 2009. View Article : Google Scholar : PubMed/NCBI
27	Score J, Curtis C, Waghorn K, et al: Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia. 20:827–832. 2006. View Article : Google Scholar : PubMed/NCBI
28	Takahashi T, Sonobe M, Kobayashi M, et al: Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 17:889–897. 2010. View Article : Google Scholar : PubMed/NCBI
29	Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 3:13–17. 2008. View Article : Google Scholar : PubMed/NCBI
30	Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 22:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
31	Yoshida A, Tsuta K, Nakamura H, et al: Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 35:1226–1234. 2011. View Article : Google Scholar : PubMed/NCBI
32	Camidge DR, Kono SA, Lu X, et al: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 6:774–780. 2011. View Article : Google Scholar : PubMed/NCBI
33	Yang P, Kulig K, Boland JM, et al: Worse disease-free survival in never-smokers with ALK⁺ lung adenocarcinoma. J Thorac Oncol. 7:90–97. 2012. View Article : Google Scholar : PubMed/NCBI
34	Wu SG, Kuo YW, Chang YL, et al: EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol. 7:98–104. 2012. View Article : Google Scholar : PubMed/NCBI